BioCryst Pharmaceuticals | BCRX - 应收帐款人



金融业
股票价格
USD
资产
USD 557.85M
现金及等价物
USD 154.97M
销售成本
USD 3.84M
流动资产
USD 484.68M
流动负债
USD 208.85M
债务
USD 828.6M
股息收益率
0
EBIT
USD 98.47M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 0.3
股本和储备
USD -454.29M
销售毛利
USD 214.41M
债务利息支出
USD 21.71M
利息收入
USD -0.13
贷款资金
USD 395.4M
市值
USD 1.81B
净收入
USD 78.4M
营业费用
USD 119.79M
营业利润
USD 98.47M
普通股股本
USD 255.27M
PE价格收益
6.84
税前利润
USD 248.02M
销售收入
USD 218.25M
销售和管理费用
USD 63.98M
股票
USD 6.06M
贸易债权人
USD 11.46M
应收帐款人
USD 110.76M


应收帐款人 更改 日
Alnylam Pharmaceuticals USD 912.74M 28.78M 2026-06
BioCryst Pharmaceuticals USD 110.76M 3.94M 2026-06
Chugai Pharma JPY 381.9B 28.96B 2026-06
Daiichi Sankyo JPY 676.92B 19.03B 2026-06
DBV Technologies USD 15.1M 1.05M 2026-03
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Gilead Sciences USD 5.06B 314M 2026-06
GlaxoSmithKline GBP 8.07B 137M 2026-06
Glaxosmithkline GBP 10.49B 40.6M 2026-03
Incyte USD 1.13B 73.7M 2026-06
Ionis Pharmaceuticals USD 58.84M 15.16M 2026-06
Karyopharm Therapeutics USD 23.36M 2.82M 2026-03
Neurocrine Biosciences USD 887M 118.9M 2026-06
Novavax USD 106.45M 72.27M 2025-12
PTC Therapeutics USD 219.92M 38.3M 2026-03
Regeneron Pharmaceuticals USD 6.57B 834.4M 2026-06
Roche Holding CHF 13.34B 1.44B 2026-06
Sarepta Therapeutics USD 393.8M 154.11M 2026-06
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Vertex Pharmaceuticals USD 2.13B 138.2M 2026-06